Cognitive Impairment Related to Cerebral Small Vessel Disease
Conditions
Interventions
Treatment group:Combination of Huatanyu Yizhi Pill and Nimodipine Tablets?
Control Group: Nimodipine Tablets?
Sponsors
Affiliated Hospital of Shaanxi University of Chinese Medicine?
Eligibility
Sex/Gender
All
Age
40 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1 Meet diagnostic criteria for cognitive impairment related to cerebral small vessel disease (CSVD) (2) Meet TCM diagnostic criteria for "dementia" (/) with phlegm-stasis syndrome (3) No communication barriers, able to complete neuropsychological assessments (4) Aged 40–85 years (inclusive), any gender (5) MoCA score <26, or subjective complaint of cognitive decline (6) Voluntary participation confirmed by signed informed consent form from the patient ??or their pre-authorized representative??, with commitment to regular follow-up
Exclusion criteria
Exclusion criteria: (1) Hereditary cerebral small vessel diseases (e.g., CADASIL, Cerebral Amyloid Angiopathy/CAA) (2) Severe underlying diseases (Cardiac/Hepatic/Renal insufficiency) (3) Concomitant vasculitis, intracranial aneurysms, or vascular malformations (4) Conditions interfering with cognitive assessment (Psychiatric disorders, Sensory/Consciousness impairments) (5) Non-CSVD causes of cognitive impairment (Neurodegenerative/Tumoral/Hydrocephalic) (6) History of alcohol or substance abuse (7) Concurrent participation in other clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in Montreal Cognitive Assessment (MoCA) Scores?; | — |
Secondary
| Measure | Time frame |
|---|---|
| Enhancement of Neuropsychological Assessment?;? ?Improvement of TCM Syndromes?;Improvement in Imaging Parameters?; | — |
Countries
China
Contacts
Public ContactYan Yongmei
Affiliated Hospital of Shaanxi University of Chinese Medicine?
Outcome results
None listed